Tìm theo
Phenylpropanolamine
Các tên gọi khác (9 ) :
  • 2-amino-1-phenylpropan-1-ol
  • Fenilpropanolamina
  • Norephedrin
  • Norephedrine
  • Phenylpropanolamin
  • Phénylpropanolamine
  • Phenylpropanolaminum
  • PPA
  • β-hydroxyamphetamine)
Thuốc dùng điều trị mắt, tai mũi họng
Thuốc Gốc
Small Molecule
CAS: 14838-15-4
ATC: R01BA01
ĐG : Amerisource Health Services Corp. , http://www.amerisourcebergen.com
CTHH: C9H13NO
PTK: 151.2056
Phenylpropanolamine has been withdrawn in Canada and the United States. In November 2000, the Food and Drug Administration (FDA) issued a public health advisory against the use of the drug.
Nhận Dạng Quốc Tế & Đặc Tính Hóa Học
Công thức hóa học
C9H13NO
Phân tử khối
151.2056
Monoisotopic mass
151.099714043
InChI
InChI=1S/C9H13NO/c1-7(10)9(11)8-5-3-2-4-6-8/h2-7,9,11H,10H2,1H3/t7-,9-/m1/s1
InChI Key
InChIKey=DLNKOYKMWOXYQA-VXNVDRBHSA-N
IUPAC Name
(1S,2R)-2-amino-1-phenylpropan-1-ol
Traditional IUPAC Name
phenylpropanolamine
SMILES
C[C@@H](N)[C@@H](O)C1=CC=CC=C1
Độ tan chảy
190-194 °C
Độ hòa tan
Freely soluble
logP
0.67
logS
-0.87
pKa (strongest acidic)
13.9
pKa (Strongest Basic)
9.37
PSA
46.25 Å2
Refractivity
44.91 m3·mol-1
Polarizability
16.98 Å3
Rotatable Bond Count
2
H Bond Acceptor Count
2
H Bond Donor Count
2
Physiological Charge
1
Number of Rings
1
Bioavailability
1
Rule of Five
true
pKa
9.44 (at 20 °C)
Dược Lực Học : Phenylpropanolamine (PPA), a sympathomimetic agent structurally similar to pseudoephedrine, is used to treat nasal congestion. Phenylpropanolamine is found in appetite suppressant formulations and with guaifenesinin in cough-cold formulations. In 2000, the FDA requested that all drug companies discontinue marketing products containing phenylpropanolamine, due to an increased risk of hemorrhagic stroke in women who used phenylpropanolamine.
Cơ Chế Tác Dụng : Phenylpropanolamine has been withdrawn in Canada and the United States. In November 2000, the Food and Drug Administration (FDA) issued a public health advisory against the use of the drug. Phenylpropanolamine acts directly on alpha- and, to a lesser degree, beta-adrenergic receptors in the mucosa of the respiratory tract. Stimulation of alpha-adrenergic receptors produces vasoconstriction, reduces tissue hyperemia, edema, and nasal congestion, and increases nasal airway patency. PPA indirectly stimulates beta-receptors, producing tachycardia and a positive inotropic effect.
Dược Động Học :
▧ Absorption :
Reduced bioavailability (about 38%) from gastrointestinal tract because of first pass metabolism by monoamine oxidase in the stomach and liver.
▧ Metabolism :
Hepatic
▧ Half Life :
2.1 to 3.4 hours.
Độc Tính : May induce ventricular extrasystoles and short paroxysms of ventricular tachycardia, a sensation of fullness in the head and tingling of the extremities; LD50=1490mg/kg (orally in rat)
Chỉ Định : For the treatment of nasal congestion, control of urinary incontinence, priapism and obesity.
Tương Tác Thuốc :
  • Acetophenazine Decreased anorexic effect, may increase psychotic symptoms
  • Alimemazine Decreased anorexic effect, may increase psychotic symptoms
  • Alseroxylon Increased arterial pressure
  • Amitriptyline The tricyclic antidepressant, amitriptyline, increases the sympathomimetic effect of phenylpropanolamine.
  • Amoxapine The tricyclic antidepressant, amoxapine, increases the sympathomimetic effect of phenylpropanolamine.
  • Bromocriptine The sympathomimetic, phenylpropanolamine, increases the toxicity of bromocriptine.
  • Chlorpromazine Decreased anorexic effect, may increase psychotic symptoms
  • Clomipramine The tricyclic antidepressant, clomipramine, increases the sympathomimetic effect of phenylpropanolamine.
  • Deserpidine Increased arterial pressure
  • Desipramine The tricyclic antidepressant, desipramine, increases the sympathomimetic effect of phenylpropanolamine.
  • Doxepin The tricyclic antidepressant, doxepin, increases the sympathomimetic effect of phenylpropanolamine.
  • Ethopropazine Decreased anorexic effect, may increase psychotic symptoms
  • Fluoxetine Risk of serotoninergic syndrome
  • Fluphenazine Decreased anorexic effect, may increase psychotic symptoms
  • Fluvoxamine Risk of serotoninergic syndrome
  • Guanethidine Phenylpropanolamine may decrease the effect of guanethidine.
  • Imipramine The tricyclic antidepressant, imipramine, increases the sympathomimetic effect of phenylpropanolamine.
  • Iobenguane Sympathomimetic that increase chances of producing a false negative imaging result
  • Isocarboxazid Increased arterial pressure
  • Linezolid Possible increase of arterial pressure
  • Mesoridazine Decreased anorexic effect, may increase psychotic symptoms
  • Methdilazine Decreased anorexic effect, may increase psychotic symptoms
  • Methotrimeprazine Decreased anorexic effect, may increase psychotic symptoms
  • Methyldopa Increased arterial pressure
  • Midodrine Increased arterial pressure
  • Moclobemide Moclobemide increases the sympathomimetic effect of phenylpropanolamine.
  • Nortriptyline The tricyclic antidepressant, nortriptyline, increases the sympathomimetic effect of phenylpropanolamine.
  • Pargyline Increased arterial pressure
  • Paroxetine Risk of serotoninergic syndrome
  • Perphenazine Decreased anorexic effect, may increase psychotic symptoms
  • Phenelzine Increased arterial pressure
  • Prochlorperazine Decreased anorexic effect, may increase psychotic symptoms.
  • Promazine Decreased anorexic effect, may increase psychotic symptoms
  • Promethazine Decreased anorexic effect, may increase psychotic symptoms.
  • Propericiazine Decreased anorexic effect, may increase psychotic symptoms.
  • Propiomazine Decreased anorexic effect, may increase psychotic symptoms
  • Protriptyline The tricyclic antidepressant, protriptyline, increases the sympathomimetic effect of phenylpropanolamine.
  • Rasagiline Increased arterial pressure
  • Reserpine Increased arterial pressure
  • Thiethylperazine Decreased anorexic effect, may increase psychotic symptoms
  • Thioridazine Decreased anorexic effect, may increase psychotic symptoms
  • Tranylcypromine Increased arterial pressure
  • Trifluoperazine Decreased anorexic effect, may increase psychotic symptoms
  • Triflupromazine Decreased anorexic effect, may increase psychotic symptoms
  • Trimipramine The tricyclic antidepressant, trimipramine, increases the sympathomimetic effect of phenylpropanolamine.
  • Venlafaxine Risk of serotoninergic syndrome
Dữ Kiện Thương Mại
Giá thị trường
Nhà Sản Xuất
  • Công ty :
    Sản phẩm biệt dược : Acutrim
  • Công ty : Cheplapharm
    Sản phẩm biệt dược : Boxogetten
  • Công ty :
    Sản phẩm biệt dược : Dexatrim
  • Công ty : Pediatrica
    Sản phẩm biệt dược : Disudrin
  • Công ty : IAE
    Sản phẩm biệt dược : Naldec
  • Công ty : Medlink
    Sản phẩm biệt dược : Nasadec
  • Công ty : Morishita-Seggs
    Sản phẩm biệt dược : Nasathera
  • Công ty :
    Sản phẩm biệt dược : Propagest
  • Công ty : Riemser
    Sản phẩm biệt dược : Recatol mono
  • Công ty :
    Sản phẩm biệt dược : Rhindecon
  • Công ty : Meda
    Sản phẩm biệt dược : Rinexin
Đóng gói
Tài Liệu Tham Khảo Thêm
drugbank
http://www.drugbank.ca/drugs/DB00397
PubChem Compound
http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=26934
PubChem Substance
http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=46508087
KEGG Compound
http://www.genome.jp/dbget-bin/www_bget?cpd:C07911
ChemSpider
http://www.chemspider.com/Chemical-Structure.25082.html
PharmGKB
http://www.pharmgkb.org/drug/PA164748965
Wikipedia
http://en.wikipedia.org/wiki/Phenylpropanolamine
Drugs.com
http://www.drugs.com/mtm/phenylpropanolamine.html
... loading
... loading